Fixing REMS program for managing drug risk requires input, co-operation, US FDA says
This article was originally published in SRA
Executive Summary
US regulators have acknowledged that the Food and Drug Administration has experienced challenges over the past five years in implementing its risk evaluation and mitigation strategy (REMS) program – under which the agency can require sponsors to submit structured plans to manage specific risks associated with prescription medicines.